XML 14 R3.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenues:    
Total revenues $ 2,829,905 $ 1,529,644
Operating expenses:    
Research and development 24,389,888 24,577,751
General and administrative 6,975,029 9,698,015
Total operating expenses 31,364,917 34,275,766
Loss from operations (28,535,012) (32,746,122)
Other income (expense):    
Interest and other income (expense), net (66,552) 312,523
Change in fair value of common stock warrants 0 (127,841)
Gain (loss) on investment in affiliated entities (750,103) 2,380,423
Net loss before income tax benefit/(provision for income tax) (29,351,667) (30,181,017)
Income tax benefit/(provision for income taxes) 62,800 (2,169,811)
Net loss (29,288,867) (32,350,828)
Net loss attributable to non-controlling interest 69,605 0
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (29,219,262) $ (32,350,828)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders    
Basic and diluted (dollars per share) $ (0.30) $ (0.36)
Weighted average number of common shares outstanding    
Basic and diluted (shares) 97,494,968 90,451,791
Revenue under collaborative research and development arrangements    
Revenues:    
Total revenues $ 2,770,712 $ 1,289,046
Revenue under collaborative research and development arrangements with affiliated entities    
Revenues:    
Total revenues 55,579 148,008
Miscellaneous revenue    
Revenues:    
Total revenues $ 3,614 $ 92,590